Hyperuricemia:
Indications for: ALOPRIM
Chemotherapy-induced hyperuricemia and hyperuricosuria when oral therapy not feasible.
Adult Dosage:
Give by IV infusion as single or in equally divided doses at 6-, 8-, or 12-hr intervals. Start 1–2 days before chemotherapy. Adjust based on serum uric acid levels. Initially 200–400mg/m2 per day; max 600mg/day. Renal impairment: CrCl 10–20mL/min: 200mg/day; <10mL/min: 100mg/day; on dialysis: 50mg every 12hrs or 100mg every 24hrs.
Children Dosage:
Give by IV infusion as single or in equally divided doses at 6-, 8-, or 12-hr intervals. Start 1–2 days before chemotherapy. Adjust based on serum uric acid levels. Initially 200mg/m2 per day; max 400mg/day. Severe renal impairment or on dialysis: consider risks/benefits prior to initiation.
ALOPRIM Warnings/Precautions:
Discontinue at 1st sign of skin rash. HLA-B*58:01 positive patients: not recommended. Consider testing for HLA-B*58:01 allele in at-risk populations prior to initiation. Pre-existing liver or renal disease (including renal impairment or history of kidney stones). Maintain adequate hydration (urine output at least 2L/day in adults) and urine alkalinization. Monitor blood counts, renal, and hepatic function periodically during early stages of therapy. Discontinue if elevated liver enzymes develop. Elderly. Pregnancy. Nursing mothers: not recommended (during and for 1 week after the last dose).
ALOPRIM Classification:
Xanthine oxidase inhibitor.
ALOPRIM Interactions:
Increased risk of skin rash with bendamustine, thiazides, ampicillin, amoxicillin. Monitor renal function with thiazides; reduce Aloprim dose. Increased bone marrow suppression with cytotoxic agents; monitor. Reduce concomitant azathioprine, mercaptopurine doses. Concomitant pegloticase may blunt the rise of serum uric acid levels and increase risk of pegloticase related anaphylaxis; discontinue and do not start Aloprim therapy. May antagonize capecitabine, fluorouracil; avoid. Antagonized by uricosurics. May potentiate oral anticoagulants, cyclosporine, theophylline; monitor. Additive CNS depressant effects with alcohol and other CNS depressants.
Adverse Reactions:
Skin rash, nausea, vomiting, renal failure/insufficiency; serious skin reactions (eg, TEN, SJS, DRESS), hepatotoxicity, myelosuppression, drowsiness.
Generic Drug Availability:
YES
How Supplied:
Vial—1
Miscellaneous urogenital disorders:
Indications for: ALOPRIM
Chemotherapy-induced hyperuricemia and hyperuricosuria when oral therapy not feasible.
Adult Dosage:
Give by IV infusion as single or in equally divided doses at 6-, 8-, or 12-hr intervals. Start 1–2 days before chemotherapy. Adjust based on serum uric acid levels. Initially 200–400mg/m2 per day; max 600mg/day. Renal impairment: CrCl 10–20mL/min: 200mg/day; <10mL/min: 100mg/day; on dialysis: 50mg every 12hrs or 100mg every 24hrs.
Children Dosage:
Give by IV infusion as single or in equally divided doses at 6-, 8-, or 12-hr intervals. Start 1–2 days before chemotherapy. Adjust based on serum uric acid levels. Initially 200mg/m2 per day; max 400mg/day. Severe renal impairment or on dialysis: consider risks/benefits prior to initiation.
ALOPRIM Warnings/Precautions:
Discontinue at 1st sign of skin rash. HLA-B*58:01 positive patients: not recommended. Consider testing for HLA-B*58:01 allele in at-risk populations prior to initiation. Pre-existing liver or renal disease (including renal impairment or history of kidney stones). Maintain adequate hydration (urine output at least 2L/day in adults) and urine alkalinization. Monitor blood counts, renal, and hepatic function periodically during early stages of therapy. Discontinue if elevated liver enzymes develop. Elderly. Pregnancy. Nursing mothers: not recommended (during and for 1 week after the last dose).
ALOPRIM Classification:
Xanthine oxidase inhibitor.
ALOPRIM Interactions:
Increased risk of skin rash with bendamustine, thiazides, ampicillin, amoxicillin. Monitor renal function with thiazides; reduce Aloprim dose. Increased bone marrow suppression with cytotoxic agents; monitor. Reduce concomitant azathioprine, mercaptopurine doses. Concomitant pegloticase may blunt the rise of serum uric acid levels and increase risk of pegloticase related anaphylaxis; discontinue and do not start Aloprim therapy. May antagonize capecitabine, fluorouracil; avoid. Antagonized by uricosurics. May potentiate oral anticoagulants, cyclosporine, theophylline; monitor. Additive CNS depressant effects with alcohol and other CNS depressants.
Adverse Reactions:
Skin rash, nausea, vomiting, renal failure/insufficiency; serious skin reactions (eg, TEN, SJS, DRESS), hepatotoxicity, myelosuppression, drowsiness.
Generic Drug Availability:
YES
How Supplied:
Vial—1
